))
Medtech Deals 'Meaningfully Rebound' in Q1
Manage episode 422896029 series 3241555
Content provided by Louis Lehot. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Louis Lehot or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
According to a recent PitchBook report, medtech M&A is on the rise, especially with cardiovascular tech and surgical robotics.Key points to note about this recent shift:▪️ Q1 2024 saw $3.3B in funding, up from $2.8B in Q4 2023▪️ Cardiovascular and surgical robotics led the charge with $2.2B and $1B, respectively, in the past year▪️ About 1/2 of the Q1 funding went to later-stage deals.This surge in deal value suggests there could be a strong rest of the year ahead for manda activity. Stabilizing public medtech valuations could further contribute to this trend, allowing for new opportunities for growth and innovation.Give this Axios article a read for more.
Discover more about Louis Lehot and explore additional professional insights on his website: https://louislehot.com
Explore Related Content:
This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit louislehotattorney.substack.com
123 episodes
Share
